CONTRAVE
Peaknaltrexone hydrochloride and bupropion hydrochloride
NDAORALTABLET, EXTENDED RELEASE
Approved
Sep 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
6
Data completeness
7/8 — Comprehensive
CONTRAVE (naltrexone hydrochloride and bupropion hydrochloride) is components: naltrexone, an opioid antagonist, and bupropion, a relatively weak inhibitor of the neuronal reuptake of dopamine and norepinephrine. Approved for combination with a reduced-calorie diet, increased physical activity to reduce excess body weight, maintain weight reduction long term in adults with obesity and 1 more indications. First approved in 2014.
Drug data last refreshed 4d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CONTRAVE is a fixed-dose combination of naltrexone (an opioid antagonist) and bupropion (a dopamine/norepinephrine reuptake inhibitor) approved for chronic weight management in adults with obesity or overweight with weight-related comorbidities. The combination targets two brain regions involved in appetite regulation (hypothalamus) and reward processing (mesolimbic dopamine circuit), though the exact neurochemical mechanism driving weight loss is not fully elucidated. Patients use it as an adjunct to reduced-calorie diet and increased physical activity.
$0.002BPart D
Peak8.1 years to LOEProduct is in peak commercial phase with modest Part D spending (~$2M in 2023); obesity treatment market expanding, but team size and investment level remain constrained.
Mechanism of Action
components: naltrexone, an opioid antagonist, and bupropion, a relatively weak inhibitor of the neuronal reuptake of dopamine and norepinephrine. Nonclinical studies suggest that naltrexone and bupropion have effects on two separate areas of the brain involved in the regulation of food intake: the…
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.